Literature DB >> 7543114

Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.

T Laursen1, J O Jørgensen, G Jakobsen, B L Hansen, J S Christiansen.   

Abstract

Endogenous GH secretion is pulsatile. Animal studies indicate that GH administered in a pulsatile manner induces growth and insulin-like growth factor I (IGF-I) generation more effectively than continuous administration. Short term human studies, however, have reported similar metabolic effects with constant and pulsatile GH delivery. This study was carried out to compare the metabolic effects of longer term continuous infusion vs. daily injections of GH. Thirteen GH-deficient patients were studied in a cross-over design. The patients were randomized to receive GH as a continuous sc infusion by means of a portable pump for 1 month and as daily sc injections (at 1900 h) for another month. An average daily GH dosage (+/- SEM) of 3.15 +/- 0.27 IU was administered during both periods. Steady state 24-h profiles of GH, IGF-I, IGF-binding proteins (IGFBPs), insulin, glucose, lipid intermediates, and other metabolites were monitored after each treatment period. At the end of each study period (at 0800 h), an oral glucose tolerance test was performed. The mean (+/- SEM) integrated levels of serum GH (micrograms per L) were higher after GH injection [2.51 +/- 0.54 (injection) vs. 1.77 +/- 0.35 (infusion); P < 0.02]. Continuous infusion induced higher nighttime than daytime GH levels (P = 0.01), indicating a diurnal variation in the absorption or clearance of GH. Serum IGF-I levels (micrograms per L) were slightly higher (P < 0.05, by analysis of variance) after continuous GH infusion [312.5 +/- 50.2 (injection) and 334.6 +/- 46.6 (infusion)]. Similarly, constant GH delivery induced higher IGFBP-3 levels (P < 0.05, by analysis of variance). Serum IGFBP-1 levels were similar on the two occasions. Daily GH injections increased daytime insulin levels (P < 0.05), whereas 24-h levels were similar (P = 0.14). The trend toward increased insulin levels after GH injections was also found during the oral glucose tolerance test (P = 0.07). Blood glucose levels were identical on the two occasions. Nocturnal levels of nonesterified fatty acids were higher (P < 0.05) after GH injection. We conclude that continuous sc infusion of GH induced serum IGF-I and IGFBP-3 levels more effectively than daily sc injections. The constant appearance of GH in the circulation did not impair glucose tolerance, but resulted in a less physiological diurnal pattern of nonesterified fatty acids. Our data do not support the concept that a pulsatile GH pattern is of critical physiological significance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543114     DOI: 10.1210/jcem.80.8.7543114

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Growth hormone enhances the recovery of hypoglycemia via ventromedial hypothalamic neurons.

Authors:  Isadora C Furigo; Gabriel O de Souza; Pryscila D S Teixeira; Dioze Guadagnini; Renata Frazão; Edward O List; John J Kopchick; Patricia O Prada; Jose Donato
Journal:  FASEB J       Date:  2019-07-31       Impact factor: 5.191

2.  The stabilization and encapsulation of human growth hormone into biodegradable microspheres.

Authors:  O L Johnson; W Jaworowicz; J L Cleland; L Bailey; M Charnis; E Duenas; C Wu; D Shepard; S Magil; T Last; A J Jones; S D Putney
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

Review 3.  Biochemical investigations in diagnosis and follow up of acromegaly.

Authors:  Katharina Schilbach; Christian J Strasburger; Martin Bidlingmaier
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  Effect of long-term treatment with recombinant human growth hormone on erythropoietin secretion in an anemic patient with panhypopituitarism.

Authors:  M Sohmiya; Y Kato
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

5.  Additive effects of intra-articular injection of growth hormone and hyaluronic acid in rabbit model of collagenase-induced osteoarthritis.

Authors:  Sang Beom Kim; Dong Rak Kwon; Hyun Kwak; Yong Beom Shin; Hyun-Jung Han; Jong Hwa Lee; Seok Hwa Choi
Journal:  J Korean Med Sci       Date:  2010-04-16       Impact factor: 2.153

6.  Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate.

Authors:  Sei Kwang Hahn; Sun Jin Kim; Myung Jin Kim; Duk Hee Kim
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

7.  The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects.

Authors:  Sowmya Surya; Jeffrey F Horowitz; Naila Goldenberg; Alla Sakharova; Matthew Harber; Andrea S Cornford; Kathy Symons; Ariel L Barkan
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

8.  Comparison of pulsatile vs. continuous administration of human placental growth hormone in female C57BL/6J mice.

Authors:  Shutan Liao; Mark H Vickers; Angharad Evans; Joanna L Stanley; Philip N Baker; Jo K Perry
Journal:  Endocrine       Date:  2016-08-11       Impact factor: 3.633

9.  A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life.

Authors:  Jeffrey L Cleland; Nathan C Geething; Jerome A Moore; Brian C Rogers; Benjamin J Spink; Chai-Wei Wang; Susan E Alters; Willem P C Stemmer; Volker Schellenberger
Journal:  J Pharm Sci       Date:  2012-06-07       Impact factor: 3.534

10.  Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement.

Authors:  Mary L Reed; George R Merriam; Atil Y Kargi
Journal:  Front Endocrinol (Lausanne)       Date:  2013-06-04       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.